UNSPSC 51281663: Paromomycin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula C23H45N5O14.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 845NU6GJPS, chemically known as o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-o-beta-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1->4))-2-deoxystreptamine sulfate (salt) but more generally known as paromomycin sulfate, which bears US NIH Compound Identifier 64144.

UNSPSC 51281663 Paromomycin sulfate is a Commodity code that nominally identifies a specific antiparasitic medication, yet recent state and local procurement activity under this code shows a pronounced mismatch with the product name. The four recent opportunities posted under this code — ranging from emergency medical supplies for a fire department, to naloxone and drug deactivation systems for community health, to generic pharmaceutical cooperative contracting, to direct-to-manufacturer prescription program design — bear no connection to paromomycin sulfate procurement. The code appears to serve as a catch-all category for health and pharmaceutical purchasing rather than targeting this specific pharmaceutical agent. State and local issuing bodies soliciting under the code include county health departments (Seminole County, Florida), municipal fire and rescue services (City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP). The work being bought ranges from emergency response medical consumables and drug-disposal systems to bulk generic pharmaceutical supply agreements and exploratory pharmacy benefit program redesign.

Geographic activity centers on Florida (Seminole County's naloxone and drug deactivation systems procurement), Texas (HHS Commission's direct-to-manufacturer prescription RFI), and Minnesota (MMCAP's multi-state generic pharmaceutical RFP serving participating states including Oregon). Representative recent opportunities include the City of Tampa's IFB 26P00145 for medical and first aid supplies to the Tampa Fire Department Rescue Division, due March 13, 2026, estimated at $700,000 and sheltered for certified Small Local Business Enterprises; Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023; and the Minnesota Department of Administration's RFP S1070000015802 under MMCAP for generic multi-source pharmaceuticals and OTC products across state and local government facilities, with proposals due March 26, 2026. The Texas HHS Commission also issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription program implementation. The code's recent activity reflects opportunistic health-sector purchasing across multiple jurisdictions rather than a focused market for the pharmaceutical agent the code nominally names.